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Abstract
Background: Clinical management of germ cell tumours (GCTs) relies on monitoring of
serum tumour markers. However, the markers a-fetoprotein (AFP), the b-subunit of human
chorionic gonadotropin (bHCG), and lactate dehydrogenase (LDH) are expressed in <60% of
GCT cases.
Objective: To test the utility of the microRNAs (miRNAs) miR-371a-3p, miR-372-3p, miR-
373-3p, and miR-367-3p as sensitive and speciﬁc GCT serum biomarkers.
Design, setting, and participants: Serum levels ofmiRNAsweremeasured in 166 consecutive
patients with GCT before and after treatment and in 106 male controls. In the ﬁrst
50 consecutive patients, all four miRNAs were measured. In the main study, only the most
sensitive miRNA was further analysed.
Outcome measurements and statistical analysis: The speciﬁcity and sensitivity of the four
miRNAs were studied using receiver operating characteristic curves. miRNA sensitivities
were compared to those of classical markers. Statistical cross-comparisons of miRNA levels
for GCT subgroups and controls were performed at various time points during treatment.
Results and limitations: Overall, miR-371a-3p performed best, with 88.7% sensitivity (95%
conﬁdence interval [CI] 82.5–93.3%) and 93.4% speciﬁcity (95% CI 86.9–97.3%) and an area
under the curve of 0.94, outperforming AFP, bHCG, and LDH (combined sensitivity 50%).
According to Kernel density estimation, the sensitivity and speciﬁcity were 86.3% and 92.5%,
respectively. miR-371a-3p levels dropped to normal after completion of treatment. The
miRNA levels correlated with treatment failure and relapse. Teratoma did not express miR-
371a-3p.
Conclusions: ThemiRNAmiR-371a-3p is a speciﬁc and sensitive novel serumGCT biomarker
that accurately correlates with disease activity. Validation of this test in a large-scale
prospective study is needed.
Patient summary: miR-371a-3p is a novel serum marker for germ cell tumours that is
expressed by 88.7% of patients and thus is farmore sensitive and speciﬁc than classical serum
wit
sso
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Monitoring of the serum biomarkers a-fetoprotein (AFP),
the b-subunit of human chorionic gonadotropin (bHCG),
and lactate dehydrogenase (LDH) is a cornerstone of
clinical management of testicular germ cell tumours
(GCTs) [1]. However, these markers are expressed in
<60% of cases, so novel sensitive markers are needed
[2]. Although many substances have been suggested as
biomarkers for GCT, none have qualified for clinical use
[3].
In 2011, microRNAs (miRNAs) of the clusters miR-
371-3 and miR-302/367 were suggested as new serum
biomarkers [4]. The miRNA molecules represent a
particular class of small RNAs consisting of approximately
20 base pairs [5]. After release from the cell, these
molecules remain stable in extracellular fluids [6] and can
be measured by quantitative polymerase chain reaction
(qPCR).
The miRNAs of the miR-371-3 and miR-302/367 clusters
were originally detected in GCT tissue [7–10] and four
independent pilot studies confirmed elevated serum levels
[11–15]. Furthermore, circulating miRNAs of the two
clusters are clearly specific for GCT because it was
demonstrated that they are absent in other malignancies
[16], andmuch higher levels of thesemiRNAs were found in
testicular vein blood than in the peripheral circulation
[17]. The goal of the present study was to further evaluate
the usefulness of miR-371a-3p, miR-372-3p, miR-373-3p,
and miR-367-3p as serum biomarkers of GCT in an
unselected large patient sample. To determine whether
the four miRNAs would be equally appropriate as serum
biomarkers, all were tested in a preliminary study consist-
ing of 50 GCT patients. The miRNA with the highest
discriminatory power was then further evaluated in a
cohort of 166 patients. We explored the utility of that
miRNA as a serum biomarker by comparing its sensitivity to
that of classical markers and by monitoring the response of
miRNA levels to treatment.Table 1 – Clinical data for patients with germ cell tumours, patients wi
main studies
Group Preliminary study
n Age (yr) Tumour diamete
Total GCT patients 50 37.0 (28.0–46.0) 27.0 (15.3–
CS1, total 40 39.0 (32.5–46.0) 25.5 (15.0–
CS1, seminoma 24 44.5 (38.8–48.3) 26.5 (15.0–
CS1, nonseminoma 16 31.0 (23.0–35.3) 25.5 (17.5–
CS2, total 6 27.0 (26.3–28.5) 19.5 (16.0–
CS2, seminoma – – –
CS2, nonseminoma 6 27.0 (26.3–28.5) 19.5 (16.0–
CS3, total 4 38.5 (28.8–46.5) 52.5 (41.3–
CS3, seminoma 1 48.0 –
CS3, nonseminoma 3 31.0 (26.5–38.5) 60.0 (52.5–
Patients with relapse – – –
Leydig cell tumours – – –
Control subjects 20 36.0 (28.3–48.3) –
GCT = germ cell tumour; CS = clinical stage. Data are presented as median (interq
a One patient is included in the CS1 seminoma group and in the group of relaps2. Patients and methods
2.1. Patients
From June 2011 to September 2015, a total of 166 patients with GCT and
12 patients with Leydig cell tumour (LCT) who were aged 18–60 yr were
prospectively enrolled from four institutions (Albertinen-Krankenhaus
Hamburg, Bundeswehrkrankenhaus Hamburg, Universita¨tsklinikum
Hamburg-Eppendorf, Klinikum Bremen-Mitte). Sixty-four participants
were brieﬂy mentioned previously in relation to a speciﬁc analysis of
miRNA levels in testicular vein blood (Table 1) [12,17].
As controls, 106 male participants from the same age group were
recruited (12 healthy men and 94 patients with benign scrotal
conditions such as hydrocele, spermatocele, epididymitis, and varico-
cele) (Table 1). The ﬁrst consecutive 50 GCT patients and 20 controls
were participants in a preliminary study that was conducted separately.
In the main study, serum samples before orchiectomy were available for
150 of the 166 GCT patients. To monitor changes in miRNA levels
secondary to chemotherapy, serum samples were repeatedly collected
(once per cycle) from 18 patients with clinical stage 2 (CS2) disease, nine
patients with CS3 disease, and ten patients experiencing relapse. Serum
aliquots were frozen and stored at 80 8C before further processing
(Supplementary methods). All patients gave informed consent. Ethics
approval was given by A¨rztekammer Bremen (reference 301, 2011).
Further clinical details are shown in Supplementary Tables 1–7.
2.2. Laboratory methods
For RNA isolation, an miRNeasy Mini Kit (Qiagen, Hilden, Germany) was
used to extract total RNA from 200 ml of serum. Reverse transcription
(RT) was performed using a TaqManMicroRNA Reverse Transcription Kit
(Applied Biosystems, Darmstadt, Germany). The RT product was
preampliﬁed, and levels of miR-371a-3p (assay 002124), miR-372-3p
(assay 000560), miR-373-3p (assay 000561), and miR-367-3p (assay
000555) were measured by qPCR using a TaqMan miRNA assay (Applied
Biosystems). Cycle threshold (Ct) values were normalised to miR-93-5p
(assay 000432) as an internal control, and the relative quantity (RQ) was
calculated using the 2DDCt method [18]. Details of the measurement
methods are described in the Supplementary methods [19].
The classical serum tumour markers AFP, bHCG, and LDH were
measured according to laboratory guidelines [20]. Preoperative values
were available for 139 patients.th Leydig cell tumours, and control subjects for the preliminary and
Main study
r (mm) n Age (yr) Tumour diameter (mm)
40.0) 166 38.5 (30.3–46.0) 29.0 (18.0–45.0)
40.0) 107 40.0 (32.0–46.5) 25.0 (15.0–38.0)
40.0) 78 a 43.0 (35.0–47.8) 25.0 (15.0–38.0)
35.8) 29 30.0 (23.0–35.0) 26.5 (19.5–39.3)
26.0) 38 39.5 (31.0–47.0) 33.5 (20.0–61.3)
17 36.0 (31.0–46.0) 40.0 (24.0–65.8)
26.0) 21 41.0 (31.0–48.0) 30.0 (17.3–52.5)
61.3) 11 36.0 (25.0–44.5) 60.0 (45.0–78.0)
1 48.0 –
62.5) 10 33.5 (25.0–41.5) 62.5 (52.5–82.3)
10 a 29.0 (26.8–39.3) –
12 46.0 (33.3–50.3) –
106 38.0 (26.0–48.0) –
uartile range).
ing patients because of relapse 2 yr after carboplatin therapy.
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Median RQ values for independent subgroups were compared using
the Mann-Whitney U test, whereas related groups were compared
using the Wilcoxon signed rank test. Bonferroni correction was
applied in the preliminary study to adjust for multiple testing. In
addition to empirical calculations, the distribution of RQ values was
modelled using Kernel density estimation to obtain a more realistic
assessment of the distribution in a larger sample size. Receiver
operating characteristic (ROC) analysis was performed to evaluate the
discriminatory power of the markers analysed. We chose RQ = 5 as
the cutoff value to evaluate sensitivity and speciﬁcity in the main
study. The frequency of categorical data was compared using the
Pearson x2 test. Multiple regression analysis was performed to
analyse the association between marker expression and tumour
diameter or pT stage. Exact 95% conﬁdence intervals (CIs) were
calculated. For values based on Kernel density estimation, 95% CIs
were calculated by bootstrapping with n = 2500 simulations. All tests
were two-sided, and signiﬁcance was assumed at p < 0.05. Statistical
analysis was performed using SPSS version 22 (IBM, Armonk, NY,
USA) and R version 3.2.3 (R Foundation for Statistical Computing,
Vienna, Austria) [21].
3. Results
3.1. Preliminary study
The preliminary study revealed a significantly higher level
of expression for each of the four miRNAs in GCT patients
compared to controls (Fig. 1A–D), with significance retained
after correction for multiple testing (p < 0.001 for all
miRNAs). Patients with metastases had higher expression
levels than those with CS1 disease, but after Bonferroni
correction this difference was only significant for miR-
371a-3p (p = 0.001) and miR-367-3p (p = 0.006). Of the four
miRNAs, miR-371a-3p had the highest ability to discrimi-
nate between patients and controls. The difference in
median RQ values for controls and patients was greatest for
miR-371a-3p, whereas the interquartile ranges for miR-
372-3p and miR-373-3p in patients overlapped consider-
ably with those for controls. Thus, of the four miRNAs
tested, miR-371a-3p had the highest sensitivity and
specificity (area under the curve [AUC] 0.943; 95% CI
0.874–0.982) according to ROC analyses with density
estimation (Fig. 1E–H).
When the four miRNAs were tested together as one
marker panel with the assumption that one increased
miRNA constituted an overall positive score, maximum
efficiency (highest Youden index) was obtained, with
sensitivity of 92% and specificity of 80%. miR-371a-3p
reached specificity of 84.7%when set to the same sensitivity
of 92%. Because the discriminatory power of miR-371a-3p
alone was at least similar to that of the miRNA panel, only
miR-371a-3p was selected for further analysis in the
extended patient sample.
3.2. Main study
Figure 2A shows the median expression of miR-371a-3p in
controls, in patients with LCTs, and in the three clinical GCT
stages in conjunction with postoperative measurements inpatients with CS1 and CS2. We observed highly significant
differences in preoperative median values between GCT
subgroups and controls or patients with LCTs. Significant
differences were also noted between preoperative and
postoperative values in CS1 and CS2 patients.
Stratifying GCT patients into various histologic sub-
groups (Fig. 2B) revealed that teratoma had very low
median expression, close to the normal range, in patients
with CS1 and CS2 disease. Among CS1 patients, miRNA
levels in seminoma and nonseminoma were significantly
different from each other and from teratoma. The median
miRNA levels for the subgroups featured in Figure 2A,B are
listed in Supplementary Table 8 with p values related to the
various cross-comparisons shown in Supplementary
Table 9.
The diagnostic sensitivity ofmiR-371a-3pwas calculated
to as 88.7% (95% CI 82.5–93.3%) using empirical data for all
150 preoperative samples and 106 controls, and the
specificity was 93.4% (95% CI 86.9–97.3%), with an AUC of
0.945 (asymptotic 95% CI 0.916–0.974). Using the density
estimation model, sensitivity was 86.3% (95% CI 79.7–
90.4%) and specificity was 92.5% (95% CI 89.0–95.9%), with
an AUC of 0.939 (95% CI 0.907–0.965) (Fig. 2C, Supplemen-
tary Fig. 1). We also found dissimilar miR expression
between localized and disseminated disease, with sensitiv-
ity of 81.4% (95% CI 72.1–87.0%) and specificity of 92.5%
(95% CI 89.0–96.1%) in CS1 (n = 107), and sensitivity of
98.6% (95% CI 94.8–99.9%) and specificity of 92.5% (95% CI
88.9–96.3%) in CS2–3 (n = 43).
In CS1 seminoma,multiple regression analysis revealed a
highly significant association between miR-371a-3p ex-
pression and tumour diameter (p < 0.001), but no associa-
tion with pT stage (Fig. 3).
Figure 4 shows the superior sensitivity of miR-371a-3p
compared to the classical GCT markers in both histologic
subgroups (all comparisons p < 0.001). For the entire group
of 139 GCT patients for whom all values were available, the
overall sensitivity of miR-371a-3p was considerably higher
than that of the combined AFP, bHCG, and LDH markers
(87.8% vs 50.4%). Further details are given in Supplementary
Table 10.
The individual repeated measurements of miR-371a-3p
among 18 CS2 patients during chemotherapy are shown in
Figure 5A. Expression of miR-371a-3p decreased in
12 patients after orchiectomy and dropped to the normal
range in the majority of patients after the first cycle of
chemotherapy, remaining there during the later course. In
one patient (case #118) miR-371a-3p expression was
approximately 20% of the starting value until cycle 3, but
then dropped to zero. On completion of therapy, most
patients had miR-371a-3p expression of almost zero; two
patients had expression of 1.5% and 2.2%, respectively, of the
starting value.
In the nine CS3 patients, miR-371a-3p expression
decreased markedly for all except one after the first cycle
of chemotherapy (Fig. 5B). No further information is
available for this patient. miR-371a-3p expression levels
in the other patients remained low until completion of
treatment.
[(Fig._1)TD$FIG]
Fig. 1 – Box plots of relative microRNA (miRNA) expression in 50 patients with germ cell tumours and 20 controls (preliminary study) for (A)
miR-371a-3p, (B) miR-372-3p, (C) miR-373-3p, and (D) miR-367-3p. The bold lines within the boxes show the median miRNA expression in patients
with CS1, CS2, and CS3 disease and controls, with box size indicating the interquartile range. The y-axis is plotted on a log10 scale. (E–H) Receiver
operating characteristic curve with value for area under the curve (AUC) and 95% confidence interval (CI) for the corresponding box plot. C = controls;
CS = clinical stage.
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[(Fig._4)TD$FIG]
Fig. 4 – Comparison of the classical markers a-fetoprotein (AFP), b-
subunit of human chorionic gonadotropin (bHCG), and lactate
dehydrogenase (LDH) with miR-371a-3p according to preoperative
measurements. The bars represent the sensitivity of bHCG (Pale orange
bars), AFP (light light orange bars), LDH (light orange bars), combined
bHCG + AFP + LDH (orange bars), and miR-371a-3p (dark orange bars)
among patients with seminoma and nonseminoma and in the entire
germ cell tumour (GCT) cohort. Error bars represent 95% confidence
intervals.
[(Fig._2)TD$FIG]
Fig. 2 – Box plots and receiver operating characteristic (ROC) curves of
miR-371a-3p expression in patients with germ cell tumours and
controls (main study). (A) Box plot of miR-371a-3p expression in
controls, in patients with Leydig cell tumours, and in patients with
clinical stage 1 (CS1), CS2, or CS3 disease. Data for preoperative patient
cohorts are shown in orange, and for postoperative cohorts in light
orange. (B) Box plot of miR-371a-3p expression in patients with
tumours of different histologic subtypes and in controls. Data for
seminomas are shown in orange, for nonseminomas in light orange,
and for teratomas in light light orange. (C) ROC curve with area under
the curve (AUC) for miR-371a-3p expression in 150 preoperative GCT
serum samples and 106 controls. The y-axis in A and B is plotted on a
log10 scale. C = controls; L = Leydig cell tumours; NS = nonseminoma;
postop = postoperative; preop = preoperative; S = seminoma;
T = teratoma.
[(Fig._3)TD$FIG]
Fig. 3 – Association between miR-371a-3p expression and tumour
diameter among 77 patients with clinical stage 1 seminoma. The
association is highly significant (p < 0.001). The adjusted R2 is
0.386. The y-axis is plotted on a log10 scale.
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nine patients with relapse, all of whom had elevated
expression levels. As with the other patients with metasta-
ses, miR-371a-3p levels decreased after the first cycle of
chemotherapy, with one exception (case #159). Levels
remained low for all patients except one (case #163), in
whom miR-371a-3p expression increased to >300% of the
starting value. In this case, the course of miR-371a-3p
[(Fig._5)TD$FIG]
Fig. 5 – Changes in miR-371a-3p levels in individual patients with
systemic disease during the course of chemotherapy. Each line denotes
an individual patient. Dotted lines represent mean values for the
cohort. The values represent percentages of the starting value. The y-
axis shows values for relative quantity and is plotted on a log10 scale in
all diagrams. (A) Patients with clinical stage 2 (CS2) disease, (B) CS3
disease, (C) relapsing disease, and (D) an individual patient with CS1
seminoma who relapsed 2 yrs after adjuvant carboplatin therapy. The
orange arrow indicates the time point of orchiectomy, and the light
orange arrows the chemotherapy courses for relapse.
E U RO P E AN URO LOGY 7 1 ( 2 0 1 7 ) 2 1 3 – 2 2 0218expression mirrored that of AFP levels, which likewise rose
to >300%, indicating tumour progression.
One patient with CS1 seminoma relapsed 2 yr after
adjuvant carboplatin treatment (Fig. 5D). Notably, this
patient had persistently high miRNA expression after
orchiectomy. The level had further increased at relapse,
but dropped to normal on remission after chemotherapy.
4. Discussion
The study results reveal that serum levels of miR-371a-3p
apparently fulfil all prerequisites for a valuable biomarker.First, miR-371a-3p is biologically specific for GCT, although,
theoretically, an immune response reaction cannot be
completely excluded. Healthy control subjects and patients
with nonmalignant scrotal disease, as well as those with
non-GCT of the testis (LCT), did not express the marker
[13,14]. Second, the marker expression correlated with
clinical stage. Patients with metastases had significantly
higher miRNA levels than CS1 cases. In CS1 seminoma, miR-
371a-3p levels correlated with tumour size. Third, miRNA
levels correlated with treatment effects. In CS1 disease,
elevated miR-371a-3p levels dropped to normal postoper-
atively, mirroring the tumour-free situation. In patients
with metastases, miR-371a-3p expression decreased with
chemotherapy to reach normal levels on completion of
therapy. Notably, patients with relapsing disease also
expressed themarker, as observed in nine cases. In addition,
failure of therapy can be highlighted by the marker, as
observed in one relapsing patient who had increasing
miRNA levels on disease progression despite chemotherapy.
It is also noteworthy that one patient with CS1 disease that
relapsed after 2 yrs had supranormal postoperative miR-
371a-3p expression. PersistentmiRNA elevationmight have
heralded pending clinical relapse. Overall, serummiR-371a-
3p levels adequately correlated with the actual state of
disease and treatment response.
The association between miRNA expression levels and
histologic subtype is unexplained. However, it could be
hypothesised that correlation between the degree of
morphologic tumour differentiation and miRNA serum
levels exists because the miR-371–3 cluster is expressed
primarily in undifferentiated stem cells [22]. This would
explain the low expression in teratoma, which represents
the GCT subtype with the highest degree of morphologic
differentiation [23]. Conversely, the higher expression of
miR-371a-3p in nonseminoma could be related to the high
proportion of embryonal carcinoma in our nonseminoma
group. This histologic subtype is biologically close to stem
cells [24]. By contrast, seminoma cells have a somewhat
higher degree of differentiation, with morphologic similari-
ty to spermatogonia [25], and thus feature lowermiR-371a-
3p expression than embryonal carcinoma.
Since 2012, pilot studies have documented the applica-
bility ofmiRNAs of the 302/367 and 371–3 clusters as serum
markers of GCT. Accordingly, it was proposed that all
miRNAs of the two clusters be used as one diagnostic panel
in clinical practice. The present study confirms that miR-
371a-3p is the miRNA with the highest ability to discrimi-
nate GCT patients from control subjects [14]. MiR-367-3p
performed second best, whereas miR-372-3p and
miR-373-3p had considerably lower discriminatory power.
The optimised quantification methods used in this study
revealed that miR-371a-3p has specificity at least identical
to the panel of four miRNAs when the sensitivity was set to
an equal value. In practice, it is probably not necessary to
use the panel of all miRNAs, as previously suggested
[13,15,26,27]. In light of the economic constraints in clinical
practice and the results of the present study, it seems
rational to use miR-371a-3p exclusively, adding only miR-
367-3p for unresolved cases.
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 2 1 3 – 2 2 0 219The diagnostic specificity of miR-371a-3p is extraordi-
narily high compared to the classical AFP, bHCG, and LDH
markers. More than 86% of GCT patients express this novel
marker. The expression is most valuable in seminoma, in
which <20% of patients express bHCG [28]. Because miRNA
expression is associated with tumour size, small CS1
seminomas may have only slightly increased levels. A
minor limitation of the utility of miR-371a-3p is its lack of
expression in teratoma. However, this finding is in
accordance with the lack of expression of classical markers
in this histologic subtype [29].
Limitations of our study include the comparatively low
number of patients with metastases. Owing to the
somewhat dissimilar expression of the new marker in
localized and systemic disease, confounding of the results
by selection is conceivable, so the clinical applicability of
the test remains uncertain so far. Long-term observational
data are missing, and it has still not been formally proven
that low miRNA levels on completion of treatment remain
low. Nevertheless, preliminary data indicate that levels
remain low during follow-up unless the disease recurs.
5. Conclusions
The promising results from pilot studies were confirmed. To
the best of our knowledge, this study is the first to use
density estimation for a large sample size to gauge the real
distribution of RQ values for GCTs and controls. The study
also provides evidence of changes in miR-371a-3p expres-
sion during chemotherapy in a fairly sizeable patient
sample and documents miR expression in relapsing
patients. miR371a-3p appears to be a highly sensitive
and specific serum GCT biomarker that can aid during
monitoring of GCT and could possibly help in sparing
radiologic examinations [30]. A prospective large-scale
validation study is under way with a view to implementing
the test in clinical practice.
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